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at market entry of each drug of interest and using a sequential propensity score 
matched cohort design. We applied four BRA metrics: number needed to treat and 
number needed to harm (NNT|NNH); incremental net benefit (INB) with maximum 
acceptable risk [MAR], INB with relative-value adjusted life years [RVALYs], and INB 
with quality-adjusted life years [QALYs]. We determined whether and when the 
bootstrapped 99% confidence interval (CI) for each metric excluded zero, indicating 
net favorability of one drug over the other. Results: For rofecoxib, all four metrics 
yielded a negative value, suggesting net favorability of ns-NSAIDs over rofecoxib, 
and the 99% CI for all but the NNT|NNH excluded the null during follow-up. For 
prasugrel, only the 99% CI for INB-QALY excluded the null, but trends in values 
over time were similar across the four metrics, suggesting overall net favorability 
of prasugrel versus clopidogrel. The 99% CI for INB-RVALY and INB-QALY excluded 
the null in the denosumab example, suggesting net favorability of denosumab over 
bisphosphonates. ConClusions: Prospective benefit-risk monitoring can be used 
to determine net favorability of a new drug in electronic healthcare data. In three 
examples, existing BRA metrics produced qualitatively similar results but differed 
with respect to alert generation. INB-QALY produced the most conclusive findings 
across the three examples.
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Qt PRolongation identification in RetRosPective studies
Ye Y., Caffrey A.R.
University of Rhode Island, Kingston, RI, USA
objeCtives: To evaluate operational definitions for cardiac events related to QT 
prolongation, such as paroxysmal ventricular tachycardia, ventricular fibrillation 
and flutter, cardiac arrest, and sudden cardiac death, in retrospective studies using 
administrative databases. Methods: Using PubMed, we searched for studies that 
retrospectively identified cardiac events related to QT prolongation in administra-
tive or claims databases and were published between January 2000 and September 
2014. Selection for full-text review was based on a preliminary review of titles and 
abstracts. Results: Our initial search yielded 988 articles from which five were 
selected for inclusion after full-text review. Case report, clinical trial, congenital long 
QT syndrome, cardiac event not related to QT prolongation, and electrocardiography 
utilization are reasons for exclusion. Seven additional articles were identified from 
the references of these articles. The twelve included articles consist of four cohort 
studies (33%), three case-control studies (25%), three validation studies (25%), and 
two descriptive studies (17%). Nine studies (75%) utilized databases from the United 
States, five (42%) of which used Medicaid data, and three (25%) used European data. 
The most common operation definitions for cardiac events related to QT prolonga-
tion were primary discharge diagnosis of long QT-related cardiac events (75%) and 
sudden cardiac death (25%). The most common administrative codes utilized were 
ICD-9 (83%) and ICD-10 (17%). The most frequently utilized ICD-9 diagnosis code 
was 427.x (100%, cardiac dysrhythmias, ICD-10: I47-49), followed by 426.x (33%, con-
duction disorders, ICD-10: I44-45), and 798.x (33%, sudden death, cause unknown, 
ICD-10: R96). Six studies (50%) reviewed medical records to validate the diagnosis 
codes. Positive predictive values ranged from 77-94% when defining cardiac events 
related to QT prolongation using ICD-9 codes 426.x or 427.x. ConClusions: In 
administrative databases, ICD-9 codes 426.x and 427.x as the principle discharge 
diagnosis or underlying cause of death are commonly used to identify cardiac events 
related to QT prolongation.
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coMPaRison of Benefit-Risk assessMent Methods foR PRosPective 
MonitoRing of newly MaRketed dRugs: a siMulation study
Gagne J.J.1, Najafzadeh M.1, Choudhry N.K.1, Bykov K.2, Kahler K.3, Martin D.P.3, Rogers J.R.2, 
Schneeweiss S.1
1Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA, 2Brigham and 
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objeCtives: We compared benefit-risk assessment (BRA) methods for determining 
whether and when sufficient evidence exists to indicate that one drug is favora-
ble over another in prospective monitoring. Methods: We simulated prospective 
monitoring of a new drug (A) versus an alternative (B) with respect to two beneficial 
and three harmful outcomes. We generated data for 1,000 iterations of six sce-
narios and applied four BRA metrics: number needed to treat and number needed 
to harm (NNT|NNH); incremental net benefit (INB) with maximum acceptable risk 
(INB-MAR); INB with relative-value adjusted life years (INB-RVALY); and INB with 
quality-adjusted life years (INB-QALY). We determined the proportion of iterations 
in which the 99% confidence interval (CI) for each metric included and excluded the 
null and we calculated mean time-to-alerting. Results: With no true difference 
in any outcome between drugs A and B, the proportion of iterations including the 
null was lowest for INB-RVALY (64%) and highest for INB-QALY (76%). When drug 
A was more effective and the drugs were equally safe, INB-QALY indicated net 
favorability of drug A in 81% of iterations, INB-MAR and INB-RVALY indicated net 
favorability in 79% of iterations, and NNT|NNH indicated net favorability in 72% of 
iterations. When drug A was safer than drug B, NNT|NNH had the highest proportion 
of iterations indicating net favorability of drug A (65%). Mean time-to-alerting was 
similar among methods across the six scenarios. ConClusions: BRA metrics can 
be useful for identifying net favorability when applied to prospective monitoring 
of a new drug versus an alternative. INB-based approaches similarly outperform 
unweighted NNT|NNH approaches.
PRM10
usage of PRoPensity scoRe, instRuMental vaRiaBle, oR Machine 
leaRning foR Real woRld data analysis
Choi S.
PAREXEL International, Billerica, MA, USA
objeCtives: It is essential to reduce potential bias by adjusting for confounders 
when performing real world data analysis. It is informative to investigate usage of 
ent to materially affect ICERs. More conservatively, assuming no treatment effect 
beyond 10-years still resulted in 0.35 life years gained, a significant gain compared to 
the 10-year horizon. Varying assumptions in different ways altered the magnitudes 
of the gains in LYs (and potentially cost-effectiveness), but not the essential conclu-
sions. ConClusions: This research confirms Gray’s suggestion of the importance 
of extending analysis time horizons when differential mortality is observed at the 
end of a study. Under any reasonable assumption applied to the extrapolation, any 
survival difference at end of study must persist to some degree beyond that time 
and therefore add to the treatment benefit observed up to the point of extrapola-
tion. Ignoring the post-study period biases clinical and cost-effectiveness results.
PRM5
coMPaRing diagnosis-Based and PRescRiPtion-Based coMoRBidity 
MeasuRes foR PRedicting health seRvice utilization and costs
Gangan N., Banahan B. III
University of Mississippi, University, MS, USA
objeCtives: Comorbidity scores are frequently used for controlling confounding in 
observational studies using administrative claims. Several comorbidity measures 
have been developed and evaluated for predicting a variety of outcomes. However, 
scores are often used with outcomes other than those included in validation studies. 
Few publications have compared the performance of different scores in predicting 
different types of outcomes. The objective of the present study was to compare the 
Charlson Comorbidity Index (CCI), a frequently used diagnosis-based comorbidity 
score, and Rx Risk, a prescription-based comorbidity score, as predictors of three 
outpatient outcomes. Methods: A retrospective analysis was conducted using 
Mississippi Medicaid medical and pharmacy claims data for the period January 2010 
to December 2011. Inclusion criteria were continuous enrolment during the observa-
tion period, not dual-eligible, and having both medical and pharmacy claims in both 
calendar years. CCI scores and Rx Risk Scores were calculated using 2010 claims. 
Scores were evaluated as predictors of outpatient visits, total outpatient costs and 
total pharmacy costs in 2011. Costs were log transformed. A base general linear 
model with age, gender, race and ethnicity was developed. Predictive ability of each 
comorbidity score was measured as the change in R2 when the score was added 
to the base model. Results: R2s for the base model were visits - 0.07, outpatient 
costs - 0.01, and pharmacy costs - 0.03. CCI and Rx Risk improved prediction for visits 
and pharmacy costs (CCI R2s; 0.10, 0.05; Rx Risk R2s; 0.13, 0.07). ConClusions: 
Although CCI is often used for outpatient outcomes, Rx Risk provides a better 
measure of comorbidity when the dependent variables are outpatient utilization or 
costs. The CCI was developed for predicting mortality during hospitalization. These 
results indicate that comorbidity scores developed for predicting outpatient out-
comes would be better for controlling for comorbidity in outpatient based studies.
PRM6
Matching-adjusted indiRec tReatMent coMPaRison and suRvival 
extRaPolation in Radioiodine-RefRactoRy diffeRentiated thyRoid 
canceR (Rai-RefRactoRy dtc)
Tremblay G.1, Holbrook T.2, Milligan G.2, Pelletier C.1
1Eisai, Woodcliff Lake, NJ, USA, 2Adelphi Real World, Manchester, UK
objeCtives: Indirect treatment comparisons (ITCs) are an important part of any 
comparative effective demonstration in the absence of head-to-head clinical trials. 
Classic ITCs can lead to biased results due to differences in patient populations and 
trial designs. These differences can be corrected for by using matching-adjusted ITC 
(MAIC) technique. Furthermore, extrapolation of survival data beyond clinical trial 
results may be required for economic evaluations. The objective of this research was 
to compare lenvatinib and sorafenib in patients with RAI-Refractory DTC using MAIC 
and survival extrapolation techniques. Methods: Mean overall survival (OS) and 
progression-free survival (PFS) outcomes were estimated by weighting lenvatinib’s 
patient level data based on baseline characteristics from sorafenib phase 3 trial 
using logistic regression. Classic ITC was performed before and after adjustment. 
Extrapolation of OS and PFS was performed using proportional hazard, acceler-
ated time failure, individual parametric models and piecewise models (Royston 
& Parmar). Results were presented as hazard ratios (HR) with confidence intervals 
(CI). Results: Unadjusted ITCs for Lenvatinib vs. placebo were 0.746(0.497; 1.119) 
for OS and 0.213(0.158; 0.288) for PFS. The MAIC provided statistically significant 
estimates of 0.577 (0.347; 0.959) for OS and 0.170(0.118; 0.254) for PFS vs. placebo. 
Unadjusted ITCs vs. sorafenib were 0.933(0.529; 1.643) and 0.362(0.245; 0.536) respec-
tively for OS and PFS; while MAIC results were 0.721(0.379; 1.373) and 0.325(0.201; 
0.526) respectively for OS and PFS. Survival extrapolation provided estimates of 7.5-
10 month of additional OS gain for Lenvatinib vs. placebo, with the MAIC extrapola-
tion showing the largest gain and a good model fit. ConClusions: This analysis 
demonstrated that in absence of head-to-head trials, MITC offers important meth-
odology to adjust for population and trial differences, especially in orphan diseases 
where limited data are available. MAIC can increase the reliability of comparative 
effectiveness data and support payers decision making.
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assessMent of net favoRaBility in electRonic healthcaRe data
Gagne J.J.1, Bykov K.2, Najafzadeh M.1, Choudhry N.K.1, Martin D.P.3, Kahler K.3, Rogers J.R.2, 
Schneeweiss S.1
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objeCtives: Benefit-risk assessment (BRA) methods can combine measures of 
benefits and risks into a single value. We examined BRA metrics for prospective 
monitoring of new drugs in electronic healthcare data. Methods: Using two 
databases, we emulated prospective monitoring of three drugs versus compara-
tors (rofecoxib vs. non-selective non-steroidal anti-inflammatory drugs [ns-NSAIDs], 
prasugrel versus clopidogrel, and denosumab versus bisphosphonates) beginning 
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data extRaction foR systeMatic Review – wheRe to look foR data 
outside the PRiMaRy PuBlication
Quigley J.M., Halfpenny N.J., Thompson J.C., Scott D.A.
ICON Health Economics, Oxford, UK
objeCtives: A common problem in systematic reviews are incomplete data extrac-
tion forms resulting in problems attempting evidence synthesis; we rarely have all 
the data for the endpoints of interest for all studies, and parameters that inform 
meta-analysis or connect networks are missing. Increased transparency in clini-
cal trial reporting means this problem is slowly disappearing. From January 2015 
the European Medicines Agency (EMA) will publish clinical study reports submit-
ted with marketing-authorisation applications for human medicines. Methods: 
We identified several data sources outside the primary publication. Standard data 
sources for systematic reviews of interventions include peer-reviewed publications, 
conference abstracts and clinical trial registries. Clinical study protocols are often 
published but are not identifiable through searches in online databases, therefore, 
to find these, systematic reviewers must visit the journal website. Manufacturer 
submissions to health regulators are also increasingly made available; these give 
detailed trial descriptions and results presented are more likely to be comprehen-
sive. Results: In a recent example in Hepatitis-C we utilised several additional 
data sources in our evidence synthesis. Clinical trial protocols were used to iden-
tify definitions of endpoints included and to fulfil aspects of the critical appraisal. 
Fibrosis stage is an accepted treatment effect modifier in Hepatitis-C; our review 
therefore collected subgroup data for this. However, this was not readily available 
in peer-reviewed publications; we thus obtained data from EMA submission docu-
ments and UK and German reimbursement submissions. Other examples include a 
2013 COPD systematic review which retrieved mortality data from the FDA website 
for three studies reporting cardiovascular-related death and for one study reporting 
overall death. ConClusions: Systematic reviewers should be aware of additional 
data sources that are publically available. Whilst peer-reviewed data is preferential, 
incorporation of this grey literature into an evidence synthesis could lead to a more 
informed overview of clinical efficacy and thereby healthcare decision making.
PRM15
investigation of RelationshiPs Between BioMaRkeRs of Potential 
haRM and cigaRette sMoking MeasuRes aMong cuRRent, Past, and 
non-sMokeRs Based on national health and nutRition exaMination 
suRvey 2007-2012
Saxena K.1, Liang Q.2, Muhammad-Kah R.2, Sarkar M.2
1Virginia Commonwealth University, Richmond, VA, USA, 2Altria Client Services Inc, Richmond, 
VA, USA
objeCtives: Assess the potential relationships between Biomarkers of Potential 
Harm (BOPH), specifically WBC, Apo lipoprotein, C-reactive protein, HDL, LDL, total 
cholesterol, and biomarkers of cigarette smoke exposure (BOE), specifically serum 
cotinine, creatinine adjusted urinary total NNAL and 1-hydroxypyrene (1-OHP), 
using National Health and Nutrition Examination Survey (NHANES) data from 2007 
till 2012. Secondary objective was to assess the relationship between BOPH and 
smoking status (past, current or never), and cigarette per day (CPD) use in current 
smokers. Methods: Data were obtained from NHANES 2007 to 2012. The study 
sample included 17,293 respondents age 21 years and above who had answered 
questions on cigarette smoking and had complete laboratory values for their bio-
markers measurement. The population was categorized as current (CS), past (PS), 
and never smokers (NS), based on self-reported responses. The exposure variables 
were the BOE, smoking status and CPD. The outcome variables were levels of the 
BOPH listed above. Weighted survey linear regression was used to estimate the 
association between exposure and outcome variables. The models were adjusted for 
age, gender, race and body mass index (BMI). Results: The mean concentrations of 
WBC (1000 cells/uL) in CS, PS and NS were 8.15, 6.97 and 6.82 respectively, and that 
of HDL (mg/dL) were 49.92, 53.23 and 53.53, respectively. A statistically significant 
correlation was observed for WBC and HDL with serum cotinine (R2= 0.133 and 
0.222), Total NNAL (R2= 0.072 and 0.210) and 1-OHP (R2= 0.090 and 0.186). Similarly, 
significant correlations for WBC and C-reactive protein with smoking status 
(R2= 0.060 and 0.101), and for WBC and HDL with CPD (R2= 0.098 and 0.160) were 
observed. ConClusions: Among all the BOPH, the correlation between WBC and 
HDL were significant with all the cigarette smoking measures. This analysis sug-
gests that WBC and HDL would be useful BOPH in studies addressing health risks 
of cigarette smoking.
PRM16
coMBining Mcda with advanced statistics to tackle challenges of 
data and judgMent unceRtainty: case study of safety assessMents
Goetghebeur M.M.1, Wagner M.1, Nikodem M.2, Zyla A.2, Micaleff A.3, Amzal B.4
1LASER Analytica, Montreal, QC, Canada, 2LASER Analytica, Krakow, Poland, 3MerckSerono SA, 
Eysins, Switzerland, 4LASER Analytica, London, UK
objeCtives: Comparative safety assessment can be challenging due to differences 
in safety profiles between comparators, scarcity of data, difficulty in establishing 
causality, and deficiencies in reporting. To address this, a method combining prag-
matic MCDA and advanced statistics was developed and tested by a panel of meth-
odologists and clinical and policy decisionmakers using a case study. Methods: 
The pragmatic MCDA model categorized adverse events (AEs) generically by their 
clinical consequences into three criteria: ‘non-serious AEs’ (AEs), ‘Non-fatal serious 
AEs’ (SAEs) and ‘Fatal AEs’ (FAEs). Panelists weighted criteria using point allocation. 
Efalizumab for plaque psoriasis, withdrawn in 2009 due to reports of deaths associ-
ated with progressive multifocal leukoencephalopathy (PML), was selected as case 
study. Odds ratios (ORs) for SAEs and AEs were estimated using Bayesian network 
meta-analysis. Incidence of PML was estimated using Poisson modelling. Panelists 
assessed efalizumab safety using a constructed scoring scale for each criterion. 
The approach was re-tested by panelists. Results: Weights for AEs, SAEs and FAEs 
ranged widely between panellist with means (ranges) of 0.06 (0.01-0.1), 0.22 (0.09-
various methods for adjusting confounders in estimating comparative effective-
ness. Methods: Systematic literature review in PubMed was conducted to iden-
tify published articles with the key words such as propensity score, instrumental 
variable analysis, inverse probability, Propensity Instrumental, Propensity Inverse 
probability, machine learning, support vector machine, CART (Classification And 
Regression Tree) is decision tree learning. Trend analysis was performed by compar-
ing proportions of methods before 2008 and after 2008. Results: 5021 articles were 
found with the key word of comparativeness effectiveness. 227 articles had the key 
word of propensity. 56 articles had the key word of instrumental. 29 articles had the 
key word of inverse probability. 20 articles had key words of both propensity and 
instrumental. 12 articles had key words of both propensity and inverse probability. 6 
articles had key word of machine learning. 6 articles had key word of CART. No article 
was found to have the key word of support vector machine. Overall 6.2% of articles 
had one of the key words, indicating usage of confounder adjustment methods in 
comparative effectiveness research. Two articles had three key words of propensity, 
Inverse probability, and instrumental. Based on Chi-square test, significant increase 
of usage with P-value < .05 in trend has been observed. ConClusions: Based on 
search result, significant increase in usage of confounder adjustment methods was 
observed since 2008. In a few articles, results from a few instrumental variable analy-
ses were conflicting with propensity score method warranting sensitivity analyses 
by employing various methods for adjustment of confounders. Also application 
of machine learning methods is recommended to find stable estimates of models 
used, especially to adjust for time dependent confounders.
PRM11
evaluating content validity of PeRfoRMance outcoMes (PeRfos): 
estaBlishing the Patient-Relevance of thRee PeRfos in elective total 
hiP RePlaceMent (ethR)
Ballinger R.S.1, Kerr C.1, Bush E.N.2
1ICON, Oxford, UK, 2Eli Lilly, Indianapolis, IN, USA
objeCtives: Performance Outcomes (PerfOs) measure tasks performed by a 
patient under the instruction of a health-care professional. PerfOs used to sup-
port FDA label claims now require content validity evidence. This study explored 
patient experience and relevance of three elective total hip replacement (eTHR) 
PerfOs: the timed up and go (TUG), four step stair climb (4SC) and long stair climb 
(LSC). Methods: Eight recent eTHR patients in the US were interviewed by tel-
ephone within 7 days of completing three PerfOs. Participants discussed their 
experience of completing the PerfOs; and how the movements, speed and level 
of difficulty corresponded to activities in their everyday lives. Interviews were 
audio-recorded, transcribed and systematically coded. Saturation was assessed by 
tabulated patient summaries from which new elements reported in each interview 
were identified. Results: The sample comprised six females and two males, with 
mean age 67 years. All participants related TUG movements to activities in their 
daily life (e.g. getting up to turn on the television) and most regularly climbed a 
few steps at home and in a similar way to the 4SC (e.g. use of handrail). Climbing 
12 or more steps (LSC) was less common. However, the majority recalled examples 
of this and felt the LSC accurately reflected movement and ability in their replaced 
hip. Two participants reported LSC completion increased their confidence and 
staircase use. Small differences between PerfOs and everyday activities/function 
were reported (e.g. TUG: the type of chair and turning towards rather than away 
from the replaced hip). Assessment of saturation suggested additional interviews 
might yield further varieties in patient experience but that sufficient consensus 
and depth was achieved to understand the relevance of the PerfOs to everyday 
function. ConClusions: New methodological approaches developed to explore 
content validity of PerfOs demonstrate the connection between three PerfOs and 
daily function of eTHR patients.
PRM12
clinical tRials RegistRies foR systeMatic Reviews – an alteRnative 
souRce foR unPuBlished data
Halfpenny N.J., Thompson J.C., Quigley J.M., Scott D.A.
ICON Health Economics, Oxford, UK
objeCtives: When conducting a systematic review it is common practice to search 
for peer-reviewed publications and conference proceedings to identify studies rel-
evant to a research question. However, information about studies is increasingly 
available through other sources and can be of importance in systematic reviews. 
Clinical trials registries (CTRs) are increasingly providing unpublished results of 
studies that can be used in systematic reviews. Clinicaltrials.gov is one of the most 
commonly used CTRs and provides search facilities that enable the identification of 
trials through common search terms. In addition, there is the potential to request 
information from study sponsors through clinicalstudydatarequest.com. This 
website is supported by several prominent study sponsors and allows reviewers to 
request access to unpublished data which may be of importance in a systematic 
review. Methods: We searched two disease areas (melanoma and juvenile idi-
opathic arthritis (JIA)) for instances where there were discrepancies in reporting 
of endpoints between peer-reviewed publications and the clinicaltrials.gov web-
page for corresponding trials. We submitted requests to clinicalstudyrequest.com 
for additional information on trials in both disease areas. Results: We identified 
additional reporting of subgroups as well as efficacy endpoints in clinicaltrials.gov 
that were not available in peer-reviewed publications. Results included one trial in 
melanoma (METRIC) which reported on only mixed line patients in a peer-reviewed 
publication; results stratified by previous therapy were available from the CTR. In 
addition, results from our search in JIA included additional reporting of efficacy out-
comes such as change in component scores from baseline. We detail length of time 
for response and issues with submission of data requests to clinicalstudyrequests.
com. ConClusions: We conclude that sources other than peer-reviewed articles 
and conference abstracts should be considered when identifying study information 
that may be relevant to a particular review. Unpublished data may be available that 
can impact a systematic review and evidence synthesis.
